Sotagliflozin attenuates cardiac dysfunction and remodeling in myocardial infarction rats
Objective: Sotagliflozin is a dual sodium-glucose co-transporter-1 and 2 (SGLT1/2) inhibitor with selectivity towards SGLT2. Previous studies showed that SGLT2 inhibitors can improve cardiac function and reduce myocardial infarction size in animal models of myocardial infarction (MI). However, it re...
Furkejuvvon:
| Váldodahkkit: | , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Elsevier
2023-11-01
|
| Ráidu: | Heliyon |
| Fáttát: | |
| Liŋkkat: | http://www.sciencedirect.com/science/article/pii/S2405844023096317 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|